Active substance : omeprazole
Form : Powder and solvent for solution for injection
Dosage : 40 mg (4 mg/ml after reconstitution with the solvent included)
Packaging : Vial with powder of active substance and solvent ampoule
Target : adults
Adults
Dafrazol® IV is indicated in adults as an alternative to oral therapy
– Treatment and prevention of recurrence of duodenal ulcers / gastric ulcers
– In combination with appropriate antibiotics, eradication of Helicobacter pylori in peptic ulcer disease.
– Treatment of reflux oesophagitis and symptomatic gastro-oesophageal reflux disease / Long-term management of patients recovered from reflux oesophagitis.
– Treatment of Zollinger-Ellison syndrome.
Adults: As an alternative to oral treatment
– In patients for whom the oral route is not appropriate, 40 mg of Dafrazol® IV is recommended once daily.
– In patients with Zollinger-Ellison syndrome, the recommended starting dose of Dafrazol® IV is 60 mg daily.
– Larger daily doses may be required and individual dosage adjustments should be made. If doses are higher than 60 mg per day, the dose should be divided into two daily doses.
Dafrazol® IV powder is reconstituted with Dafrazol® IV solvent into a solution for intravenous injection. After reconstitution, the injection should be given slowly over at least 2 minutes at a maximum rate of 4 ml per minute.
Prescription drugs. Please contact your doctor.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma